section name header

Pronunciation

moe-EKS-i-pril

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: ace inhibitors

Indications

REMS


Action

  • Angiotensin-converting enzyme (ACE) inhibitors block the conversion of angiotensin I to the vasoconstrictor angiotensin II. ACE inhibitors also prevent the degradation of bradykinin and other vasodilatory prostaglandins. ACE inhibitors also plasma renin levels and aldosterone levels. Net result is systemic vasodilation.
Therapeutic effects:
  • Lowering of BP in hypertensive patients.

Pharmacokinetics

Absorption: 13% bioavailability as moexiprilat following oral administration ( by food).

Distribution: Crosses the placenta.

Protein Binding: Moexipril: 90%; Moexiprilat: 50–70%.

Metabolism/Excretion: Converted by liver and GI mucosa to moexiprilat, the active metabolite; 13% excreted in urine, 53% excreted in feces.

Half-Life: Moexipril: 1 hr; Moexiprilat: 2–9 hr ( in renal impairment).

Time/Action Profile

(antihypertensive effect with chronic dosing)

ROUTEONSETPEAKDURATION
POwithin 1 hr4 wkup to 24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, chest pain, edema

Derm: flushing, rash

F and E: hyperkalemia

GI: diarrhea, dyspepsia

GU: impaired renal function

MS: myalgia

Neuro: dizziness, fatigue, headache

Resp: cough

Misc: ANGIOEDEMA, flu-like symptoms

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Univasc